Nimbex (Cisatracurium Besilate)

Cisatracurium besilate competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine‑induced depolarization of skeletal muscle fibers. This inhibition produces dose‑dependent muscle relaxation, and the drug is eliminated mainly by Hofmann degradation, a temperature‑ and pH‑dependent process.

The dosing regimen for Nimbex is individualized and set by the prescribing clinician based on the patient’s weight, clinical condition, and the intended duration of neuromuscular blockade. Standard practice involves an initial bolus followed by titrated infusion, but exact amounts must be determined by a qualified healthcare professional.

Safety data for cisatracurium besilate in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with obstetric specialists is recommended.

To order Nimbex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain logistics if required), and any necessary import documentation.

Nimbex (cisatracurium) is often compared with atracurium, another non‑depolarizing blocker. Cisatracurium has a more predictable onset and duration, lower histamine release, and is less dependent on renal or hepatic function for elimination, making it preferable in patients with organ impairment.

Nimbex should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use to maintain sterility and potency.

Nimbex is administered intravenously, typically as an initial bolus dose followed by a continuous infusion or supplemental boluses as needed. Administration is performed by trained healthcare professionals who monitor neuromuscular function and vital signs throughout the procedure.

Serious risks include anaphylaxis, prolonged neuromuscular blockade leading to extended paralysis, severe hypotension, and cardiac arrhythmias. Prompt recognition and supportive measures, such as airway management and cardiovascular support, are essential if these events occur.

Nimbex is contraindicated in patients with known hypersensitivity to cisatracurium, its excipients, or other non‑depolarizing neuromuscular blockers. Caution is also advised in individuals with severe hepatic or renal impairment, as well as in patients receiving other agents that potentiate neuromuscular blockade.